BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen Z, Shao T, Gao W, Fu H, Collier TL, Rong J, Deng X, Yu Q, Zhang X, Davenport AT, Daunais JB, Wey HY, Shao Y, Josephson L, Qiu WW, Liang S. Synthesis and Preliminary Evaluation of [11 C]GNE-1023 as a Potent PET Probe for Imaging Leucine-Rich Repeat Kinase 2 (LRRK2) in Parkinson's Disease. ChemMedChem 2019;14:1580-5. [PMID: 31365783 DOI: 10.1002/cmdc.201900321] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Ni R. PET imaging in animal models of Parkinson’s disease. Behavioural Brain Research 2023;438:114174. [DOI: 10.1016/j.bbr.2022.114174] [Reference Citation Analysis]
2 Chen Z, Chen J, Chen L, Yoo CH, Rong J, Fu H, Shao T, Coffman K, Steyn SJ, Davenport AT, Daunais JB, Haider A, Collier L, Josephson L, Wey HY, Zhang L, Liang SH. Imaging Leucine-Rich Repeat Kinase 2 In Vivo with 18F-Labeled Positron Emission Tomography Ligand. J Med Chem 2022. [PMID: 36256881 DOI: 10.1021/acs.jmedchem.2c00551] [Reference Citation Analysis]
3 Kumar S, Behl T, Sehgal A, Chigurupati S, Singh S, Mani V, Aldubayan M, Alhowail A, Kaur S, Bhatia S, Al-Harrasi A, Subramaniyan V, Fuloria S, Fuloria NK, Sekar M, Abdel Daim MM. Exploring the focal role of LRRK2 kinase in Parkinson's disease. Environ Sci Pollut Res Int 2022. [PMID: 35147886 DOI: 10.1007/s11356-022-19082-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Bidesi NSR, Vang Andersen I, Windhorst AD, Shalgunov V, Herth MM. The role of neuroimaging in Parkinson's disease. J Neurochem 2021;159:660-89. [PMID: 34532856 DOI: 10.1111/jnc.15516] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
5 Chen X, Zhang Q, Zhang Y, Fang J, Jiang D, Mou Z, Liu H, Su R, Wang C, He F, Chen X, Xie F, Pan X, Li Z. 18F-Labelled pyrrolopyrimidines reveal brain leucine-rich repeat kinase 2 expression implicated in Parkinson's disease. Eur J Med Chem 2021;214:113245. [PMID: 33582389 DOI: 10.1016/j.ejmech.2021.113245] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Malik N, Kornelsen R, McCormick S, Colpo N, Merkens H, Bendre S, Benard F, Sossi V, Schirrmacher R, Schaffer P. Development and biological evaluation of[18F]FMN3PA & [18F]FMN3PU for leucine-rich repeat kinase 2 (LRRK2) in vivo PET imaging. Eur J Med Chem 2021;211:113005. [PMID: 33248850 DOI: 10.1016/j.ejmech.2020.113005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Rideout HJ, Chartier-Harlin MC, Fell MJ, Hirst WD, Huntwork-Rodriguez S, Leyns CEG, Mabrouk OS, Taymans JM. The Current State-of-the Art of LRRK2-Based Biomarker Assay Development in Parkinson's Disease. Front Neurosci 2020;14:865. [PMID: 33013290 DOI: 10.3389/fnins.2020.00865] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
8 Mori W, Yamasaki T, Hattori Y, Zhang Y, Kumata K, Fujinaga M, Hanyu M, Nengaki N, Zhang H, Zhang MR. Radiosynthesis and evaluation of 4-(6-[18F]Fluoro-4-(5-isopropoxy-1H-indazol-3-yl)pyridin-2-yl)morpholine as a novel radiotracer candidate targeting leucine-rich repeat kinase 2. RSC Med Chem 2020;11:676-84. [PMID: 33479667 DOI: 10.1039/c9md00590k] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Tolosa E, Vila M, Klein C, Rascol O. LRRK2 in Parkinson disease: challenges of clinical trials. Nat Rev Neurol 2020;16:97-107. [PMID: 31980808 DOI: 10.1038/s41582-019-0301-2] [Cited by in Crossref: 183] [Cited by in F6Publishing: 185] [Article Influence: 91.5] [Reference Citation Analysis]